Quest PharmaTech Inc (QPT):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Quest PharmaTech Inc (QPT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3344
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Quest PharmaTech Inc (Quest), formerly Altachem Pharma Ltd is a pharmaceutical company that develops antibody based immunotherapeutic products for the treatment of cancer. The company develops products for treatment of cancer by combining immunotherapeutic antibodies with immunoglobulin G or E, chemotherapy, immune-adjuvants, or photodynamic therapy. It owns and utilizes photodynamic therapy technology for oncology and dermatology applications. It offers products such as anti CA125 MAb oregovomab, anti MUC1 MAb AR20.5 and SL052. Quest’s anti CA125 MAb Oregovomab is an immunotherapeutic product for the treatment of ovarian cancer. The company’s SL052 is an injectable formulation that is in phase I clinical trials used for the treatment of prostate cancer. Quest is headquartered in Edmonton, Alberta, Canada.

Quest PharmaTech Inc (QPT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Quest PharmaTech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Quest PharmaTech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Quest PharmaTech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Quest PharmaTech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Quest PharmaTech Inc, Medical Devices Deals, 2012 to YTD 2018 9
Quest PharmaTech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Quest PharmaTech Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
OncoQuest Acquires Immuno-Photodynamic Therapy Assets from Quest Pharma for USD2 Million 11
Quest PharmaTech To Acquire AllergoOncology Technology Of Advanced Immune Therapeutics 12
Venture Financing 13
OncoQuest Raises USD13 Million in Venture Financing 13
Partnerships 14
OncoQuest Enters into Agreement with Tesaro 14
OncoQuest and Shenzhen Hepalink Pharma Form Joint Venture 15
Quest PharmaTech Enters Into Co-Development Agreement With AD Biotech 16
Licensing Agreements 17
Quest PharmaTech Enters into Licensing Agreement with Bioceltran 17
Quest PharmaTech Enters Into Licensing Agreement With University Of California At Los Angeles For Cancer Treatment 18
Quest PharmaTech Enters Into Licensing Agreement With Oncovir For Hiltonol 19
Quest PharmaTech Enters Into Licensing Agreement With Stanford University For Anti-MUC1 IgE Technology 20
Equity Offering 21
OncoQuest Raises USD6 Million in Private Placement of Shares 21
Quest Pharma Raises USD1.34 Million in Private Placement of Shares upon Exercise of Warrants 22
OncoQuest Raises USD13 Million in Private Placement of Preference Shares 23
Quest PharmaTech Raises USD1.5 Million in Private Placement of Shares 24
Quest PharmaTech Raises USD0.8 Million in Private Placement of Units 25
Quest PharmaTech Completes Private Placement Of Units For US$1 Million 26
Quest PharmaTech Announces Private Placement Of Shares For US$7.7 Million 27
Quest PharmaTech Completes Private Placement Of Shares For US$0.5 Million 28
Asset Transactions 29
OncoQuest Acquires Immuno-Photodynamic Therapy Assets from Quest Pharma for USD2 Million 29
Acquisition 30
Quest PharmaTech to Acquire 32% Stake in Natural Rf Life Sciences for USD0.4 Million 30
Quest PharmaTech Inc – Key Competitors 31
Quest PharmaTech Inc – Key Employees 32
Quest PharmaTech Inc – Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Recent Developments 34
Corporate Communications 34
Jul 19, 2017: Quest PharmaTech Appoints Mr. Mark Lievonen, former President of Sanofi Pasteur Limited, to the Board of Directors 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Quest PharmaTech Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Quest PharmaTech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Quest PharmaTech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Quest PharmaTech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Quest PharmaTech Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Quest PharmaTech Inc, Medical Devices Deals, 2012 to YTD 2018 9
Quest PharmaTech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
OncoQuest Acquires Immuno-Photodynamic Therapy Assets from Quest Pharma for USD2 Million 11
Quest PharmaTech To Acquire AllergoOncology Technology Of Advanced Immune Therapeutics 12
OncoQuest Raises USD13 Million in Venture Financing 13
OncoQuest Enters into Agreement with Tesaro 14
OncoQuest and Shenzhen Hepalink Pharma Form Joint Venture 15
Quest PharmaTech Enters Into Co-Development Agreement With AD Biotech 16
Quest PharmaTech Enters into Licensing Agreement with Bioceltran 17
Quest PharmaTech Enters Into Licensing Agreement With University Of California At Los Angeles For Cancer Treatment 18
Quest PharmaTech Enters Into Licensing Agreement With Oncovir For Hiltonol 19
Quest PharmaTech Enters Into Licensing Agreement With Stanford University For Anti-MUC1 IgE Technology 20
OncoQuest Raises USD6 Million in Private Placement of Shares 21
Quest Pharma Raises USD1.34 Million in Private Placement of Shares upon Exercise of Warrants 22
OncoQuest Raises USD13 Million in Private Placement of Preference Shares 23
Quest PharmaTech Raises USD1.5 Million in Private Placement of Shares 24
Quest PharmaTech Raises USD0.8 Million in Private Placement of Units 25
Quest PharmaTech Completes Private Placement Of Units For US$1 Million 26
Quest PharmaTech Announces Private Placement Of Shares For US$7.7 Million 27
Quest PharmaTech Completes Private Placement Of Shares For US$0.5 Million 28
OncoQuest Acquires Immuno-Photodynamic Therapy Assets from Quest Pharma for USD2 Million 29
Quest PharmaTech to Acquire 32% Stake in Natural Rf Life Sciences for USD0.4 Million 30
Quest PharmaTech Inc, Key Competitors 31
Quest PharmaTech Inc, Key Employees 32
Quest PharmaTech Inc, Subsidiaries 33

List of Figures
Quest PharmaTech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Quest PharmaTech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Quest PharmaTech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Quest PharmaTech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Quest PharmaTech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Quest PharmaTech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Quest PharmaTech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Quest PharmaTech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Quest PharmaTech Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Quest PharmaTech Inc (QPT):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • East-Central Iowa Rural Electric Cooperative:企業の発電所・SWOT分析2018
    East-Central Iowa Rural Electric Cooperative - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, inf …
  • Challenger Ltd.:企業の戦略・SWOT・財務情報
    Challenger Ltd. - Strategy, SWOT and Corporate Finance Report Summary Challenger Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Total SA (FP):企業の財務・戦略的SWOT分析
    Total SA (FP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Nine Dragons Paper (Holdings) Limited:戦略・SWOT・企業財務分析
    Nine Dragons Paper (Holdings) Limited - Strategy, SWOT and Corporate Finance Report Summary Nine Dragons Paper (Holdings) Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Polarcus Ltd (PLCS):企業の財務・戦略的SWOT分析
    Summary Polarcus Ltd (Polarcus) is a marine geophysical company that provides towed streamer data acquisition and imaging services. The company provides marine acquisition services such as vessel specifications, increasing efficiency, managing emissions to air, managing emissions to sea, polar code …
  • Mitsubishi Heavy Industries, Ltd.:企業の戦略・SWOT・財務情報
    Mitsubishi Heavy Industries, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Mitsubishi Heavy Industries, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • ABM Industries Incorporated (ABM):企業の財務・戦略的SWOT分析
    ABM Industries Incorporated (ABM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Kina Petroleum Ltd (KPL):石油・ガス:M&Aディール及び事業提携情報
    Summary Kina Petroleum Limited (KPL) is an upstream oil and gas company that focuses on exploration, development and production activities. It has operations in Papua New Guinea (PNG) and Australia. The company focuses on participating in highly prospective oil and gas acreage positions near to prov …
  • Enviva Partners LP (EVA):企業の財務・戦略的SWOT分析
    Enviva Partners LP (EVA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Tricida Inc (TCDA):製薬・医療:M&Aディール及び事業提携情報
    Summary Tricida Inc (Tricida), formerly Trilypsa Inc is a clinical-stage pharmaceutical and drug discovery company. The company discovers and develops novel non-absorbed therapies for the treatment of renal, metabolic and cardiovascular diseases. Its lead drug candidate TRC101, is under clinical dev …
  • Nishat Mills Ltd:企業の戦略・SWOT・財務情報
    Nishat Mills Ltd - Strategy, SWOT and Corporate Finance Report Summary Nishat Mills Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Swiss Life Holding Ltd:企業のM&A・事業提携・投資動向
    Swiss Life Holding Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Swiss Life Holding Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Envases del Plata S.A.:企業の戦略・SWOT・財務情報
    Envases del Plata S.A. - Strategy, SWOT and Corporate Finance Report Summary Envases del Plata S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Ohio State University Comprehensive Cancer Center-製薬・医療分野:企業M&A・提携分析
    Summary Ohio State University Comprehensive Cancer Center (OSUCCC), a subsidiary of Ohio State University is a healthcare institution that provides medical and academic education services. The institute provides education, research, and patient care services. Its service portfolio includes cancer di …
  • Accugenomics Inc:医療機器:M&Aディール及び事業提携情報
    Summary Accugenomics Inc (Accugenomics) is a developer of oncology molecular diagnostics. The company develops and markets gene expression tests to diagnose and monitor cancer treatment. It offers gene expression tests including lung cancer risk test, standardized BCR-ABL molecular diagnostics test …
  • Sir Robert McAlpine Ltd:企業の戦略的SWOT分析
    Sir Robert McAlpine Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Ausgrid:企業の戦略的SWOT分析
    Ausgrid - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • PTT Global Chemical Public Co Ltd (PTTGC):企業の財務・戦略的SWOT分析
    PTT Global Chemical Public Co Ltd (PTTGC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • TOA Corporation:企業の戦略・SWOT・財務情報
    TOA Corporation - Strategy, SWOT and Corporate Finance Report Summary TOA Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Intersect ENT Inc (XENT):企業の財務・戦略的SWOT分析
    Summary Intersect ENT Inc (Intersect), formerly Sinexus Inc is a medical device company that offers chronic sinusitis solutions. The company offers steroid releasing implants and mini steroid implants. It provides surgical solutions for patients, disease recurrence with recurrent symptoms. Intersect …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆